SAB Biotherapeutics (SABS) Cash & Equivalents (2020 - 2026)

SAB Biotherapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $20.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 263.8% year-over-year to $20.5 million; the trailing twelve-month figure through Mar 2026 stood at $20.5 million (up 263.8% YoY), and the FY2025 full-year result was $10.5 million, up 18.03% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $20.5 million, up from $10.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $56.6 million in Q4 2023, with the low at $2.4 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $15.4 million across 5 years, with a median of $13.1 million in 2023.
• The largest YoY upside for Cash & Equivalents was 279.31% in 2024 against a maximum downside of 84.27% in 2024.
• SAB Biotherapeutics' Cash & Equivalents stood at $15.0 million in 2022, then surged by 275.93% to $56.6 million in 2023, then sank by 84.27% to $8.9 million in 2024, then gained by 18.03% to $10.5 million in 2025, then jumped by 95.38% to $20.5 million in 2026.
• The last three Cash & Equivalents figures came in at $20.5 million (Q1 2026), $10.5 million (Q4 2025), and $29.4 million (Q3 2025), per Business Quant data.